Myocardial Perfusion Scan: Definition, Clinical Significance, and Overview

Posted on February 28, 2026 | by drheartcare

Myocardial Perfusion Scan Introduction (What it is)

A Myocardial Perfusion Scan is a cardiac imaging test that assesses blood flow to the heart muscle.
It is a functional diagnostic test rather than an anatomic map of the coronary arteries.
It is commonly used to evaluate suspected or known coronary artery disease and myocardial ischemia.
It is typically performed with a stress component and a rest component using a radioactive tracer.

Clinical role and significance

A Myocardial Perfusion Scan helps clinicians answer a central cardiology question: is the myocardium receiving adequate perfusion at rest and during increased demand? This matters because many patients with coronary artery disease (CAD) have flow-limiting stenoses that may not cause symptoms at rest but can produce ischemia during exertion or pharmacologic stress.

Clinically, it is used for diagnosis and risk stratification. By distinguishing reversible perfusion defects (suggesting inducible ischemia) from fixed defects (often consistent with prior myocardial infarction and scar, though patterns can vary), it contributes to decisions about further testing and potential pathways such as intensified medical therapy, coronary angiography, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG), depending on the overall clinical context.

Beyond ischemia detection, a Myocardial Perfusion Scan often provides gated functional information such as left ventricular ejection fraction (LVEF), regional wall motion, and ventricular volumes. These parameters support broader assessment in conditions such as heart failure, cardiomyopathy evaluation, and preoperative risk assessment, while recognizing that each institution’s protocols and reporting elements can differ.

Indications / use cases

Typical clinical scenarios where a Myocardial Perfusion Scan may be considered include:

Evaluation of chest pain or dyspnea when CAD is suspected and functional ischemia assessment is desired
Risk stratification in patients with known CAD (e.g., prior PCI, prior CABG, or prior myocardial infarction)
Assessment of ischemic burden to support decisions about invasive angiography or revascularization (varies by clinician and case)
Preoperative cardiac risk assessment for selected non-cardiac surgeries when functional capacity is unclear and results may change management
Clarifying the significance of intermediate coronary lesions identified on other testing (e.g., coronary computed tomography angiography) in some care pathways
Evaluation of symptoms in patients with baseline electrocardiogram (ECG) abnormalities that can limit standard exercise treadmill ECG interpretation (e.g., left bundle branch block)
Follow-up evaluation in patients with recurrent symptoms after revascularization, when clinically appropriate
Complementary assessment in selected cardiomyopathy or heart failure evaluations, particularly when ischemic etiology is part of the differential diagnosis

Contraindications / limitations

A Myocardial Perfusion Scan is not universally suitable, and appropriateness depends on patient stability, stress modality, and institutional practice. Common limitations and situations where alternative approaches may be preferred include:

Unstable clinical status (e.g., ongoing ischemic symptoms, decompensated heart failure, serious arrhythmias, or hemodynamic instability), where urgent evaluation and treatment pathways may take priority
Contraindications to stress testing in general, especially for exercise or pharmacologic stress (selection varies by clinician and case)
Pharmacologic stress agent limitations, such as bronchospastic lung disease for certain vasodilators, or conduction disease without appropriate pacing support for some agents (agent choice varies by institution)
Pregnancy is often a relative contraindication due to ionizing radiation exposure; risk–benefit assessment is individualized
Inability to cooperate with imaging requirements, such as difficulty lying flat or remaining still, which may reduce image quality
Body habitus and attenuation artifacts (e.g., diaphragm or breast attenuation) that can reduce specificity and require artifact mitigation strategies
Balanced ischemia in multivessel or left main disease can make relative perfusion appear “uniform,” potentially reducing sensitivity in specific scenarios
Microvascular dysfunction may cause symptoms with less prominent focal perfusion defects; interpretation depends on tracer behavior and clinical context
Radiation exposure, which is generally low-to-moderate compared with many diagnostic imaging tests but remains an important consideration

How it works (Mechanism / physiology)

A Myocardial Perfusion Scan relies on the principle that myocardial blood flow increases during stress in healthy coronary circulation. In the presence of flow-limiting coronary stenoses, the affected region may demonstrate relatively reduced tracer uptake during stress compared with rest, reflecting inducible ischemia.

Physiologic principle

A radiotracer is injected intravenously and distributed in proportion to myocardial perfusion and tracer characteristics.
Images are acquired to show the relative distribution of tracer in the left ventricular myocardium.
Stress imaging is compared with rest imaging to distinguish stress-induced perfusion abnormalities from resting abnormalities.

Relevant cardiac anatomy and pathophysiology

The test evaluates perfusion of the myocardium, primarily the left ventricle, which is supplied by the coronary arteries (left main, left anterior descending, left circumflex, and right coronary artery distributions).
Perfusion abnormalities may correlate with epicardial coronary stenosis, prior infarction, or mixed ischemia/scar patterns, although correlation is not perfect and depends on clinical and technical factors.

Onset, duration, reversibility

Onset/duration in the pharmacologic sense does not apply because this is an imaging test rather than a therapy. The concept of reversibility applies to imaging patterns: a defect present on stress images that improves or normalizes at rest is typically described as reversible, while a persistent defect is often described as fixed. Interpretation and differential diagnosis can vary by clinician and case, especially when artifacts or non-ischemic cardiomyopathies are present.

Myocardial Perfusion Scan Procedure or application overview

A typical workflow is organized to compare perfusion at stress and at rest. Specific steps vary by protocol, tracer, scanner type, and institution.

Evaluation/exam – Review symptoms, cardiac history, medications, and ability to exercise.
– Baseline vitals and ECG are commonly obtained, with attention to rhythm and conduction abnormalities.
Diagnostics planning – Selection of stress method: exercise stress (treadmill/bicycle) or pharmacologic stress (vasodilator or inotrope-based protocols).
– Consideration of factors that affect test interpretation (e.g., left bundle branch block, paced rhythm, prior infarction).
Preparation – Patient instructions often include avoiding certain substances or medications that can interfere with pharmacologic stress agents (exact instructions vary by institution).
– Establish intravenous access for tracer injection and potential stress agent administration.
Intervention/testing (stress and tracer injection) – Stress is performed to increase myocardial demand or induce coronary vasodilation.
– The radiotracer is injected at a protocol-defined time relative to peak stress or pharmacologic infusion.
Image acquisition – Imaging is typically performed using a gamma camera (SPECT, single-photon emission computed tomography) or PET (positron emission tomography), depending on availability.
– Many protocols include gated imaging synchronized with the ECG to estimate LVEF and wall motion.
Immediate checks – Monitoring continues until the patient is stable, especially after pharmacologic stress.
– The imaging team checks for technical adequacy and may repeat views if motion artifact is significant.
Follow-up/monitoring – Results are interpreted alongside clinical data (symptoms, ECG, troponin trends when relevant, and pretest probability).
– Next steps vary by clinician and case and may include medical optimization, additional imaging, or invasive coronary angiography.

Types / variations

Common variations of Myocardial Perfusion Scan include differences in stress modality, imaging platform, and protocol design.

Stress modality
Exercise stress perfusion imaging: combines functional capacity information, symptoms, blood pressure response, and ECG changes with perfusion imaging.
Pharmacologic stress perfusion imaging: used when exercise is not feasible or when an exercise ECG is less interpretable; vasodilator-based approaches are common.
Imaging platform
SPECT Myocardial Perfusion Scan: widely available; uses gamma-emitting tracers such as technetium-based agents or thallium (choice varies by institution).
PET Myocardial Perfusion Scan: often offers higher spatial resolution and may allow absolute myocardial blood flow quantification depending on tracer and software.
Protocol structure
Rest–stress vs stress–rest ordering: chosen to match clinical scenario and lab workflow.
One-day vs two-day protocols: selected based on patient factors and imaging quality considerations (varies by institution).
Attenuation correction: may be performed using hardware/software methods; some systems incorporate low-dose CT for attenuation correction depending on device design.
Reporting enhancements
Gated perfusion for LVEF and wall motion
Transient ischemic dilation and other supportive markers (interpretation varies by institution)

Advantages and limitations

Advantages:

Provides a direct assessment of functional ischemia rather than anatomy alone
Helps with risk stratification by estimating extent and severity of perfusion abnormalities
Often includes LVEF and regional wall motion information via gated imaging
Can be used when resting ECG abnormalities limit treadmill ECG-only testing
Supports evaluation of symptomatic patients with known CAD after prior PCI or CABG in appropriate contexts
Offers a structured, widely taught framework for interpreting ischemia vs scar patterns

Limitations:

Uses ionizing radiation, with dose dependent on protocol, tracer, and equipment
Image quality can be affected by attenuation artifacts and patient motion
Relative perfusion imaging can be less sensitive in balanced ischemia or diffuse multivessel disease
Diagnostic performance depends on pretest probability, stress adequacy, and technical factors
Pharmacologic stress agents have contraindications and may cause transient side effects (agent selection varies by clinician and case)
Findings may be less specific in certain conduction patterns (e.g., left bundle branch block) depending on stress method and interpretation approach
Does not directly visualize coronary plaque morphology the way coronary CT angiography can

Follow-up, monitoring, and outcomes

Follow-up after a Myocardial Perfusion Scan focuses on integrating imaging results with the broader clinical picture rather than the scan result alone. Outcomes and subsequent monitoring typically depend on:

Clinical risk profile: age, diabetes, chronic kidney disease, smoking history, and prior cardiovascular events
Symptom burden and stability: exertional angina pattern, dyspnea, and functional limitation
Extent and pattern of perfusion abnormality: reversible vs fixed defects, distribution across coronary territories, and associated gated function findings
Left ventricular function: reduced LVEF or significant wall motion abnormalities may shift risk assessment and management priorities
Comorbidities and competing diagnoses: anemia, lung disease, valvular disease, and non-cardiac chest pain syndromes can influence interpretation and next steps
Therapy and adherence: outcomes are influenced by guideline-directed medical therapy where indicated (e.g., lipid management, antihypertensives) and lifestyle measures; specifics vary by clinician and case
Revascularization status: prior PCI/CABG and graft or stent-related considerations may affect the diagnostic question being asked

Monitoring intervals are not universal. Repeat testing is generally driven by a change in symptoms, a new clinical event, or a management decision point, and varies by clinician and case.

Alternatives / comparisons

Myocardial ischemia and CAD can be evaluated through multiple complementary pathways. The best choice depends on the patient’s presentation, baseline ECG, ability to exercise, renal function, local expertise, and test availability.

Exercise treadmill ECG (without imaging)
Advantages: no radiation, simpler, provides exercise capacity and symptom correlation.
Limitations: reduced accuracy with baseline ECG abnormalities and provides no perfusion map.
Stress echocardiography
Advantages: no ionizing radiation, evaluates wall motion and valves, can assess hemodynamics.
Limitations: image quality can be limited by acoustic windows; ischemia detection relies on wall motion change rather than tracer perfusion.
Coronary CT angiography (CCTA)
Advantages: strong anatomic assessment of coronary plaque and stenosis; helpful in selected low-to-intermediate risk chest pain pathways.
Limitations: anatomic stenosis does not always equal functional ischemia; requires iodinated contrast and depends on heart rate control and calcium burden.
Cardiac magnetic resonance (CMR) stress perfusion
Advantages: no ionizing radiation; can evaluate function, perfusion, and scar (late gadolinium enhancement) in one exam.
Limitations: availability varies; gadolinium use is constrained in some kidney disease contexts; patient tolerance issues (claustrophobia, devices) can apply.
Invasive coronary angiography
Advantages: definitive anatomic assessment and enables PCI when appropriate; can incorporate physiologic assessment (e.g., fractional flow reserve) depending on practice.
Limitations: invasive with procedural risks; typically reserved for higher-risk presentations or when noninvasive tests suggest actionable disease.
Observation/serial biomarkers and ECGs (acute care pathways)
In acute chest pain evaluation, serial ECGs and troponin testing guide immediate risk assessment; noninvasive imaging is usually considered after stabilization and depends on the pathway used (varies by institution).

Myocardial Perfusion Scan Common questions (FAQ)

Q: Is a Myocardial Perfusion Scan painful?
Most people experience only brief discomfort from intravenous cannulation. During stress (exercise or pharmacologic), symptoms such as shortness of breath, flushing, or chest tightness can occur, but they are monitored closely. The experience varies by stress method and individual response.

Q: Do I need anesthesia or sedation?
Anesthesia is not typically used for a Myocardial Perfusion Scan. Patients are generally awake and able to communicate symptoms during stress and imaging. Sedation may be considered in unusual circumstances (for example, severe anxiety), but this varies by institution and case.

Q: How long does the test take?
Timing depends on whether a one-day or two-day protocol is used and on scanner availability. The process often includes waiting periods between tracer injection and image acquisition. Exact duration varies by protocol and institution.

Q: What does “reversible” versus “fixed” defect mean?
A reversible defect generally indicates reduced tracer uptake during stress with improvement at rest, a pattern commonly associated with inducible ischemia. A fixed defect persists on both stress and rest images and is often consistent with prior infarction/scar, though artifacts and other conditions can mimic this pattern. Final interpretation depends on the full dataset, including gated function and image quality.

Q: How safe is the radiation exposure?
The scan uses ionizing radiation, and the dose varies by tracer, protocol, and equipment. Laboratories aim to keep exposure as low as reasonably achievable while obtaining diagnostic images. Whether the test is appropriate involves weighing potential benefit against radiation considerations (varies by clinician and case).

Q: What is the typical cost range?
Costs vary widely based on country, insurance coverage, outpatient vs inpatient setting, tracer type, and facility billing practices. Hospital-based imaging centers and independent imaging facilities may have different pricing structures. For accurate estimates, patients typically need institution-specific information.

Q: When will I get results, and how long do they “last”?
Preliminary impressions may be available soon after image acquisition, while finalized reports may take longer depending on workflow. Results reflect myocardial perfusion at the time of testing and do not guarantee future status because CAD can progress or symptoms can change. Repeat testing is usually driven by clinical changes or decision points rather than a fixed timeframe.

Q: Are there activity restrictions after the scan?
Most people can resume usual activities shortly after completion, but instructions depend on how the stress portion was performed and how the patient feels afterward. Some individuals may need a short observation period, particularly after pharmacologic stress. Post-test guidance varies by institution and case.

Q: What factors can make the scan harder to interpret?
Patient motion, attenuation artifacts, high body mass, and certain ECG conduction patterns can affect interpretation. Submaximal stress, caffeine interference with some pharmacologic agents, and multivessel “balanced” ischemia can also reduce diagnostic clarity. Imaging teams use protocol adjustments and quality checks to mitigate these issues when possible.

Q: Does a normal Myocardial Perfusion Scan rule out coronary artery disease?
A normal scan can indicate a lower likelihood of clinically significant flow-limiting ischemia under the tested conditions, but it does not exclude all CAD (for example, non-obstructive plaque or microvascular dysfunction). Clinical context, pretest probability, and other findings remain important. Next steps vary by clinician and case.